Edwards Lifesciences Competitive Intelligence & Landscape

Edwards Lifesciences' core products and services revolve around patient-focused innovative technologies for structural heart conditions. These include transcatheter heart valves, transcatheter mitral and tricuspid technologies, surgical valve technologies, and implantable heart failure management solutions [edwards.com]. The company also provides various resources for early detection, condition management, and treatment options, along with support for clinical research and trials [edwards.com].

Edwards Lifesciences was incorporated in Delaware in 1999 [ir.edwards.com/resources/investor-faqs/corporate-faqs/default.aspx]. The company is headquartered in the United States [ir.edwards.com/resources/investor-faqs/corporate-faqs/default.aspx]. Bernard J. Zovighian serves as the Chief Executive Officer [edwards.com/about-us/our-leaders]. The company's mission is rooted in a patient-focused culture, aiming to deliver life-changing innovations through world-class evidence and partnerships with clinicians and healthcare stakeholders [edwards.com/about-us/who-we-are].

Healthcare professionals can access product ordering details via Product Ordering and the Edwards Ordering Store. The ordering store allows users to navigate by business unit, add items to a cart, and proceed with shipping and checkout steps. Account management features are also available for updating user information, managing address books, and viewing order history. Detailed product specifications and ordering information, such as for the PASCAL Precision System, can be found within product brochures and technical specification documents available for download on relevant product pages Pascal precision system overview.

For their advanced hemodynamic monitoring solutions, Edwards Lifesciences provides a variety of sensors, catheters, software, and monitoring systems. Examples include the HemoSphere advanced monitoring platform, Swan-Ganz Catheters with the FastCCO algorithm for rapid flow insights, the ClearSight system for noninvasive continuous hemodynamic monitoring, and the VolumeView System for volumetric and advanced hemodynamic parameters Advanced haemodynamic monitoring solutions.

Edwards Lifesciences also offers reimbursement information to assist providers with appropriate coding, coverage, and payment for procedures involving their products Reimbursement. This suggests that while direct pricing isn't advertised, the company supports healthcare providers in navigating the financial aspects of utilizing their medical devices. Information about specific product models can be searched for on their eIFU (electronic Instructions for Use) portal eIFU home.

Job openings at Edwards Lifesciences span various locations, including their corporate headquarters in Irvine, California, which houses nearly 5,000 employees [edwards.com/careers/locations/irvine]. Other key locations with active hiring include Draper, Utah [edwards.com/careers/locations/draper], Limerick, Ireland with a new manufacturing plant [edwards.com/careers/locations/ireland], Singapore, known for its modern manufacturing facilities [edwards.com/careers/locations/singapore], and Mississauga, Ontario, Canada [edwards.com/careers/locations/canada].

A notable recent job opening is for a Data Scientist, Transcatheter Heart Valve (THV) in Irvine, California, posted just eight days ago [edwards.com/job/38251/data-scientist]. This role, within the Clinical Affairs team, highlights Edwards Lifesciences' dedication to generating extensive clinical evidence and leveraging data science to improve patient outcomes through their innovative transcatheter heart valve technologies.

Furthermore, Edwards Lifesciences actively invests in future talent through programs like the 18-month Engineering Technical Development Program (TDP). This program offers diverse rotations across various businesses and functions, aiming to accelerate participants' transition to technical leadership careers and shape the future of the industry through innovation [edwards.com/careers/university-recruiting/engineering-technical-development-program-tdp]. These initiatives signal a strong strategic focus on continuous innovation and the development of breakthrough technologies to improve patient lives.

In the first quarter of 2026, Edwards Lifesciences reported significant growth, with sales increasing by 16.7% to $1.65 billion. Constant currency sales growth for the same period was 12.7%. Transcatheter Aortic Valve Replacement (TAVR) sales also saw a notable increase of 14.4% to $1.20 billion, with constant currency TAVR sales growing 11.0%. Additionally, Transcatheter Mitral and Tricuspid Technologies (TMTT) sales reached $173 million, driven by repair and replacement therapies. The company's diluted earnings per share (EPS) for Q1 2026 was $0.66, with an adjusted EPS of $0.78 [https://www.edwards.com/newsroom/news/2026-04-23-edwards-lifesciences-reports-first-quarter-results-1bcd27a][https://ir.edwards.com/financials/financial-results/default.aspx].

The company also reported solid results for the fourth quarter of 2025, with sales growing 13.3% to $1.57 billion, and constant currency sales up 11.6%. TAVR sales in Q4 2025 were $1.16 billion, representing a 12.0% increase, while TMTT sales grew over 40% to $156 million [https://www.edwards.com/newsroom/news/2026-02-10-edwards-lifesciences-reports-fourth-quarter-result-cbac793]. For the full year 2025, sales grew 11.5%, or 10.7% in constant currency [https://www.edwards.com/newsroom/news/2026-02-10-edwards-lifesciences-reports-fourth-quarter-result-cbac793]. Furthermore, in the third quarter of 2025, sales increased by 14.7% to $1.55 billion [https://www.edwards.com/pr/newsroom/news/2025-10-30-edwards-lifesciences-reports-third-quarter-results-dde7693].

Edwards Lifesciences was spun off from Baxter on April 1, 2000, at which time shareholders received one Edwards share for every five shares of Baxter stock. On May 27, 2010, the company executed a two-for-one stock split [https://ir.edwards.com/resources/investor-faqs/stock-faqs/default.aspx]. While specific fundraising rounds or new acquisitions are not detailed in the provided search results, it is noted that the Edwards Lifesciences Critical Care division is now part of BD (Becton, Dickinson and Company) [https://edwards.com/]. The company continues to raise its fiscal year 2026 constant currency sales growth guidance to 9% [https://www.edwards.com/newsroom/news/2026-04-23-edwards-lifesciences-reports-first-quarter-results-1bcd27a].

Edwards Lifesciences consistently engages with healthcare professionals by sponsoring and attending significant industry events. For example, they will be at EuroPCR 2025 in Paris, featuring two symposia with educational live cases and activities at their booth and training village [https://info.edwards.com/europcr2025]. Similarly, they are a presence at the American Association for Thoracic Surgery (AATS) 105th Annual Meeting, hosting expert-led lunch and evening symposia to discuss topics like the KONECT RESILIA aortic valved conduit and mitral valve lifetime management [https://info.edwards.com/AATS2025.html]. The company also plans to be at GISE 2025 in Milano, presenting two symposia on innovations in aortic stenosis and mitral/tricuspid valve care, alongside hands-on Lifetime Management tutorials [https://info.edwards.com/GISE2025].

Beyond medical conferences, Edwards Lifesciences is involved in various financial and investor events. Their executives frequently present at notable healthcare conferences, such as the Barclays and Leerink Partners Global Healthcare Conferences [https://www.edwards.com/newsroom/news/2026-02-19-edwards-lifesciences-to-present-at-the-barclays-an] and the BofA Securities Health Care Conference [https://www.edwards.com/newsroom/news/2026-04-28-edwards-lifesciences-to-present-at-the-bofa-securi-9d24de9]. They also host earnings conference calls, like the Q1 2026 Edwards Lifesciences Earnings Conference Call [https://ir.edwards.com/events-presentations/event-details/2026/Q1-2026-Edwards-Lifesciences-Earnings-Conference-Call/default.aspx].

Furthermore, Edwards Lifesciences provides extensive educational resources through their dedicated platform, Edwards Learning Network, which includes videos, webinars, and podcasts from leading clinicians [https://education.edwards.com/]. They also offer educational webinars, videos, and assets related to their surgical heart products and services, notifying healthcare professionals about future symposia, forums, and conference activities [https://www.edwards.com/healthcare-professionals/products-services/surgical-heart]. In 2024, they sponsored three educational symposia at STS 2024, focusing on topics such as minimally invasive surgery and mitral valve replacement [https://info.edwards.com/STSEvents2024.html].